Short answer
Bioventus Inc. (BVS) filed its Q3 2025 10-Q quarterly report on Nov 4, 2025 for the quarter ended Sep 27, 2025. Quarterly revenue was $139M (down 0.2% year over year) with net income of $3M.
Q3 2025 key financials · XBRL
- Revenue
- $139M
- −0.2% YoY · −6.1% QoQ
- Net income
- $3M
- +165.4% YoY · −57.7% QoQ
- Operating margin
- 8.1%
- Gross margin
- 68.0%
- EPS (diluted)
- $0.05
- +171.4% YoY · −54.5% QoQ
Source: XBRL data from the Bioventus Inc. (BVS) Q3 2025 10-Q on SEC EDGAR. USD.
Bioventus Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q3 revenue $138.651M, down $0.313M or 0.2% YoY
- Operating margin 8.1% vs 2.6% YoY; gross margin 68.0% vs 67.3%
- Best segment Surgical Solutions, U.S. sales $44.981M, up 9.3%; worst Restorative Therapies, International sales $2.951M, down 34.3%
- Refinancing added $300.0M term loan and $100.0M revolver; expected annual interest savings $2.0M
- TalisMann and StimTrial limited U.S. release in Q3, broader rollout planned for early 2026
Risk Factors
- Newly added rebate risk: payer claims-system changes could significantly increase HA viscosupplement rebate volumes
- Most material update: CMS 2026 Medicare Part B rule may alter bona fide service-fee treatment and reduce HA product reimbursement
- Regulatory risk: Final Rule published October 31, 2025, with impact on ASP reporting still under review
- Market risk: proposed healthcare reforms and executive orders could create downward pressure on HA product pricing
- Financial risk: inadequate rebate reserves if payer data is delayed, inaccurate, or unexpectedly increases
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Bioventus Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.